Disclaimer: All information provided herein by Cedar Grove Capital Management, LLC (“Cedar Grove Capital”) is for informational purposes only and does not constitute investment advice or an offer or solicitation to buy or sell an interest in a private fund or any other security. An offer or solicitation of an investment in a private fund will only be made to accredited investors pursuant to a private placement memorandum and associated documents.
Cedar Grove Capital may change its views about or its investment positions in any of the securities mentioned in this document at any time, for any reason or no reason.
Students can get access to our research at a reduced rate by clicking here.
Hims and Hers Health (HIMS) has been quite the story this year and it’s barely been two months. We’ve put together our report post-Q4 earnings for you all, highlighting our skepticism of management achieving guidance without massively abusing the personalized loophole.
We are short HIMS and our 20-page report highlights the six topics we break down as you can see on page 1.
As a reminder, the work we share with you all is work that we’re incredibly proud of. Our coverage of this name has been very thorough, well thought out, and backed by data and in-depth research, coupled with working at their competitor previously.
If you have enjoyed our continued coverage, and this report as well, please consider sharing our newsletter with others who are looking for high-quality work.
As always, if you have any questions, don’t hesitate to reach out.
Please find the downloadable report after the disclaimer below.
Until next time,
Paul Cerro | Cedar Grove Capital
Personal Twitter: @paulcerro
Fund Twitter: @cedargrovecm